{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:24:14Z","timestamp":1787293454944,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostatic involvement by bladder urothelial carcinoma is uncommon, and prostatic stromal invasion usually indicates aggressive tumor biology and poor prognosis. Such patients may present with prostatic enlargement or a mass at the bladder neck-prostate junction, while serum prostate-specific antigen (PSA) may remain within the normal range. This diagnostic overlap may lead to clinical confusion with benign prostatic hyperplasia or primary prostatic tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 54-year-old man was admitted with urinary frequency, urgency, dysuria, and intermittent gross hematuria. Serum PSA on admission was 2.1 ng\/mL. Imaging suggested a mass at the bladder neck-prostate junction with an indistinct boundary between the bladder and prostate. After transurethral resection of a bladder lesion, pathology and immunohistochemistry indicated high-grade invasive urothelial carcinoma. Tumor cells expressed CK20, GATA3, and p63, partially expressed CK7 and Uroplakin III, and were negative for PSA and NKX3.1. The patient subsequently underwent radical cystectomy, ileal conduit urinary diversion, and pelvic lymph-node dissection. Postoperative pathology revealed high-grade bladder urothelial carcinoma with invasion of the prostatic stroma and capsule, staged as pT4aN0M0, with lymphovascular invasion, perineural invasion, and a positive prostatic urethral margin. PD-L1 expression was low (TPS &amp;lt;1%, IC &amp;lt;1%), and HER2 was negative. Because no neoadjuvant systemic therapy had been given and the final pathology showed pT4a disease with a positive margin, adjuvant systemic therapy was recommended and initiated. The patient received only approximately one week of platinum-based chemotherapy plus immunotherapy; treatment was discontinued because of poor tolerance and substantial financial burden. Three months after surgery, the patient developed low back pain. Whole-body bone scintigraphy and SPECT\/CT demonstrated multiple bone metastases involving the L2 and L4 vertebrae and posterior elements, bilateral iliac bones, the left acetabular rim, and the right inferior pubic ramus. He subsequently received denosumab combined with conformal intensity-modulated radiotherapy to vertebral metastatic lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that a normal PSA level does not exclude prostatic involvement by bladder-derived urothelial carcinoma. For patients with bladder neck or prostatic masses, especially those with normal PSA but imaging evidence of bladder-prostate junction involvement, an immunohistochemical panel including GATA3, CK7, CK20, p63, Uroplakin III, PSA, and NKX3.1 should be used early for differential diagnosis. Prostatic stromal invasion combined with lymphovascular invasion, perineural invasion, and a positive surgical margin may indicate highly aggressive disease and an increased risk of early distant metastasis, requiring intensified postoperative risk assessment, systemic treatment decision-making, and close follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1910163","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:36:54Z","timestamp":1787290614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Urothelial carcinoma of the bladder with prostatic stromal invasion and early postoperative bone metastases: a case report"],"prefix":"10.3389","volume":"6","author":[{"given":"Cheng","family":"Wang","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Urology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Urology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.023","article-title":"Re: EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"86","author":"de Jong","year":"2024","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/annonc\/mdr354","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: An Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.01.027","article-title":"Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance","volume":"37","author":"Shen","year":"2006","journal-title":"Hum Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S162441","article-title":"Case report of a primary prostatic urothelial carcinoma patient with sustained fever","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07171.x","article-title":"Prostatic involvement by urothelial carcinoma of the bladder: Clinicopathological features and outcome after radical cystectomy","volume":"100","author":"Ayyathurai","year":"2007","journal-title":"BJU Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA: A Cancer J For Clin"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/pas.0000000000000238","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate: Report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3233\/blc-160086","article-title":"Impact of the level of urothelial carcinoma involvement of the prostate on survival after radical cystectomy","volume":"3","author":"Moschini","year":"2017","journal-title":"Bladder Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.02.023","article-title":"Differential expression of GATA-3 in urothelial carcinoma variants","volume":"45","author":"Liang","year":"2014","journal-title":"Hum Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000178","article-title":"Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: A diagnostic pitfall","volume":"38","author":"Gordetsky","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0000000000000143","article-title":"Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma","volume":"23","author":"Hoang","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2016.06.14","article-title":"Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma","volume":"50","author":"Oh","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08558.x","article-title":"Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology","volume":"104","author":"Barocas","year":"2009","journal-title":"BJU Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyr013","article-title":"Depth and origin of prostatic involvement by urothelial carcinoma: Prognostic significance and staging interpretation","volume":"41","author":"Kiyoshima","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","article-title":"Palliative radiation therapy for bone metastases: Update of an ASTRO evidence-based guideline","volume":"7","author":"Lutz","year":"2017","journal-title":"Pract Radiat Oncol"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1910163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:36:55Z","timestamp":1787290615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1910163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":23,"alternative-id":["10.3389\/fruro.2026.1910163"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1910163","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1910163"}}